Changes for page Neurodiagnoses

Last modified by manuelmenendez on 2025/03/03 22:46
From version 14.1
edited by manuelmenendez
on 2025/01/27 23:58
Change comment: There is no comment for this version
To version 4.3
edited by manuelmenendez
on 2025/01/27 22:57
Change comment: There is no comment for this version

Summary

Details

Page properties
Content
... ... @@ -2,10 +2,9 @@
2 2  (((
3 3  (% class="container" %)
4 4  (((
5 -= //A new tridimensional diagnostic framework for CNS conditions// =
5 += Neurodiagnoses =
6 6  
7 -This project is focused on developing a novel nosological and diagnostic framework for neurological diseases by using advanced AI techniques and integrating data from neuroimaging, biomarkers, and biomedical ontologies.
8 -We aim to create a structured, interpretable, and scalable diagnostic tool.
7 +This project is focused on developing a novel nosological and diagnostic framework for neurological diseases. Using advanced AI techniques and integrating data from neuroimaging, biomarkers, and biomedical ontologies, we aim to create a structured, interpretable, and scalable diagnostic tool.
9 9  )))
10 10  )))
11 11  
... ... @@ -13,70 +13,15 @@
13 13  (((
14 14  (% class="col-xs-12 col-sm-8" %)
15 15  (((
16 -= What is this about and what can I find here? =
15 += What can I find here? =
17 17  
18 -== **Overview** ==
17 +* `/docs`: Documentation and contribution guidelines.
18 +* `/code`: Machine learning pipelines and scripts.
19 +* `/data`: Sample datasets for testing. - `/outputs`: Generated models, visualizations, and reports.
19 19  
20 -The //Tridimensional Diagnostic Framework// redefines how neurodegenerative diseases (NDDs) are classified by focusing on:
21 += Who has access? =
21 21  
22 -* **Axis 1**: Etiology (genetic/sporadic and environmental factors).
23 -* **Axis 2**: Molecular Markers (biomarkers and proteinopathies).
24 -* **Axis 3**: Neuroanatomoclinical correlations (linking clinical symptoms to structural changes in the nervous system).
25 -
26 -[[Neurodegenerative diseases can be studied and classified in a tridimensional scheme with three axes: anatomic–clinical, molecular, and etiologic. CSF, cerebrospinal fluid; FDG, fluorodeoxyglucose; MRI, magnetic resonance imaging; PET, positron emission tomography.>>image:tridimensional.png||alt="tridimensional view of neurodegenerative diseases"]]
27 -
28 -This methodology enables:
29 -
30 -* Greater precision in diagnosis.
31 -* Integration of incomplete datasets using AI-driven probabilistic modeling.
32 -* Stratification of patients for personalized treatment.
33 -
34 -== **Diagnostic Axes** ==
35 -
36 -* (((
37 -**Axis 1: Etiology**
38 -
39 -* //Description//: Focuses on genetic and sporadic causes, identifying risk factors and potential triggers.
40 -* //Examples//: APOE ε4 as a genetic risk factor, or cardiovascular health affecting NDD progression.
41 -* //Tests//: Genetic testing, lifestyle and cardiovascular screening.
42 -)))
43 -* (((
44 -**Axis 2: Molecular Markers**
45 -
46 -* //Description//: Analyzes primary (amyloid-beta, tau) and secondary biomarkers (NFL, GFAP) for tracking disease progression.
47 -* //Examples//: CSF amyloid-beta concentrations to confirm Alzheimer’s pathology.
48 -* //Tests//: Blood/CSF biomarkers, PET imaging (Tau-PET, Amyloid-PET).
49 -)))
50 -* (((
51 -**Axis 3: Neuroanatomoclinical**
52 -
53 -* //Description//: Links clinical symptoms to neuroanatomical changes, such as atrophy or functional impairments.
54 -* //Examples//: Hippocampal atrophy correlating with memory deficits.
55 -* //Tests//: MRI volumetrics, FDG-PET, neuropsychological evaluations.
56 -)))
57 -
58 -== **Applications** ==
59 -
60 -This system enhances:
61 -
62 -* **Research**: By stratifying patients, reduces cohort heterogeneity in clinical trials.
63 -* **Clinical Practice**: Provides dynamic diagnostic annotations with timestamps for longitudinal tracking.
64 -
65 -== Who has access? ==
66 -
67 67  We welcome contributions from the global community. Let’s build the future of neurological diagnostics together!
68 -
69 -== How to Contribute ==
70 -
71 -* Access the `/docs` folder for guidelines.
72 -* Use `/code` for the latest AI pipelines.
73 -* Share feedback and ideas in the wiki discussion pages.
74 -
75 -== Key Objectives ==
76 -
77 -* Develop interpretable AI models for diagnosis and progression tracking.
78 -* Integrate data from Human Phenotype Ontology (HPO), Gene Ontology (GO), and other biomedical resources.
79 -* Foster collaboration among neuroscientists, AI researchers, and clinicians.
80 80  )))
81 81  
82 82  
... ... @@ -86,11 +86,6 @@
86 86  {{toc/}}
87 87  {{/box}}
88 88  
89 -== Main contents ==
90 -
91 -* `/docs`: Documentation and contribution guidelines.
92 -* `/code`: Machine learning pipelines and scripts.
93 -* `/data`: Sample datasets for testing.
94 -* `/outputs`: Generated models, visualizations, and reports.
33 +
95 95  )))
96 96  )))
tridimensional.png
Author
... ... @@ -1,1 +1,0 @@
1 -XWiki.manuelmenendez
Size
... ... @@ -1,1 +1,0 @@
1 -149.8 KB
Content
Collaboratory.Apps.Collab.Code.CollabClass[0]
Public
... ... @@ -1,1 +1,1 @@
1 -Yes
1 +No
XWiki.XWikiRights[3]
Allow/Deny
... ... @@ -1,1 +1,0 @@
1 -Allow
Levels
... ... @@ -1,1 +1,0 @@
1 -view
Users
... ... @@ -1,1 +1,0 @@
1 -XWiki.XWikiGuest
XWiki.XWikiRights[4]
Allow/Deny
... ... @@ -1,1 +1,0 @@
1 -Allow
Groups
... ... @@ -1,1 +1,0 @@
1 -XWiki.XWikiAllGroup
Levels
... ... @@ -1,1 +1,0 @@
1 -view